Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunologic factors in primary progressive multiple sclerosis.

Reinhard Hohlfeld1

  • 1Institute for Clinical Neuroimmunology, University of Munich, Klinikum Grosshadern, Marchioninistr. 15, D-81366, Munich, Germany. hohlfeld@neuro.mpg.de

Multiple Sclerosis (Houndmills, Basingstoke, England)
|June 29, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026
Same author

Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial.

Multiple sclerosis and related disorders·2025
Same author

Multiple sclerosis and gut microbiota: Lachnospiraceae from the ileum of MS twins trigger MS-like disease in germfree transgenic mice-An unbiased functional study.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Perceptual rivalry in neuroscience, magic and philosophy.

Brain : a journal of neurology·2025
Same author

Twin study identifies early immunological and metabolic dysregulation of CD8<sup>+</sup> T cells in multiple sclerosis.

Science immunology·2024
Same author

Correction: Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis.

The Journal of experimental medicine·2022

Primary progressive multiple sclerosis (PPMS) shows distinct immunological profiles compared to relapsing MS. Brain-derived neurotrophic factor (BDNF) may play a protective role in multiple sclerosis (MS) lesions, potentially explaining glatiramer acetate (GA) therapy effects.

Area of Science:

  • Neuroimmunology
  • Clinical Neurology

Background:

  • Primary progressive multiple sclerosis (PPMS) is clinically and pathologically distinct from relapsing forms of multiple sclerosis (MS).
  • Existing research suggests PPMS patients may exhibit unique immunologic profiles, differing from both healthy controls and relapsing MS patients.
  • The role of neuroprotective factors like brain-derived neurotrophic factor (BDNF) in MS pathogenesis and treatment is an emerging area of investigation.

Purpose of the Study:

  • To investigate potential immunologic distinctions between PPMS and relapsing MS.
  • To explore the presence and significance of brain-derived neurotrophic factor (BDNF) in MS lesions and its potential role in glatiramer acetate (GA) therapy.

Main Methods:

  • Comparative analysis of cytokine, chemokine receptor, and adhesion molecule expression profiles in PPMS versus relapsing MS patients and healthy controls.

Related Experiment Videos

  • Investigation of BDNF production by activated immune cells in MS lesions.
  • Assessment of BDNF receptor presence in MS tissue.
  • Evaluation of BDNF production by glatiramer acetate (GA)-specific T cells.

    • Main Results:

    • Immunologic profiles in PPMS patients showed similarities to healthy controls, contrasting with relapsing MS patients, particularly regarding cytokine and adhesion molecule expression.
    • Activated immune cells in MS lesions produce the neuroprotective factor BDNF.
    • BDNF receptors are present in MS tissue.
    • Glatiramer acetate (GA)-specific T cells produce BDNF, independent of T helper cell phenotype (Th1 or Th2).

    Conclusions:

    • The findings suggest potential immunologic differences between PPMS and relapsing MS.
    • The production of BDNF in MS lesions and by GA-specific T cells supports a concept of 'protective inflammation' and suggests a novel mechanism for GA therapy's efficacy.
    • Further research is needed to clarify the extent to which this BDNF-mediated mechanism is present across different forms of MS.